Bioactivity and immunoactivity of growth hormone during dynamic testing of patients with acromegaly.
We have used the Nb2 cell proliferation bioassay for lactogenic hormones to investigate the biological activity of hGH in sera of patients with acromegaly. The specificity of the assay has been improved by the use of monoclonal antibodies to block the activity of individual lactogenic hormones. Disease activity in patients was assessed by scoring signs and symptoms, and by measuring IGF-I concentrations in some patients. Patients with a wide spectrum of disease activity were studied using a TRH test. hGH concentrations were measured by bioassay, RIA and immunoradiometric assay (IRMA) at 0, 20 and 60 min after injection of TRH. There was a high degree of correlation between log10 of all hGH concentrations measured by bioassay and RIA (r = 0.995, P less than 0.0001), between bioassay and IRMA (r = 0.990, P less than 0.0001), and between RIA and IRMA (r = 0.995, P less than 0.0001). In contrast to previous reports, we found no evidence for changes in the bioactivity of hGH secreted after pituitary stimulation.
Baldwin
A L
AL
Department of Chemical Pathology, King's College School of Medicine and Dentistry, London, UK.
Aston
R
R
Butler
J
J
Buchanan
C
C
Norman
M
M
D000172:Acromegaly / Q000276:immunology*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000032:analysis; D001681:Biological Assay; D002455:Cell Division; D002461:Cell Line, Transformed; D005260:Female; D013006:Growth Hormone / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay
D000911:Antibodies, Monoclonal; D013006:Growth Hormone